• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Acadia slims Nuplazid label expansion bid in hopes of clinching Alzheimer's dementia...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 21, 2021 at 10:22: AM
via Acadia plans to resubmit its application for Nuplazid, also known as pimavanserin, to treat hallucinations and delusions associated with dementia, homing in specifically on patients with Alzheimer’s disease psychosis (ADP), the company said early this week. The San Diego-based company is targeting the first quarter of 2022 for its resubmission.

article source
 




Top Bottom
Back
Quote